Unity Bio soars on positive mid-stage data for eye drug

Unity Biotechnology

01/11/2022 12:13

** Shares of drugmaker Unity Biotechnology  UBX.O  jump ~25%
to $3.51 before the bell 
    ** UBX says a single injection of its drug UBX1325 shows
statistically significant improvements in vision in patients
with diabetic macular edema in week 24 vs a sham treatment
 urn:newsml:reuters.com:*:nGNX2ZFlqr  
    ** Macular edema is the most common cause of vision loss in
diabetic patients
    ** Co adds UBX1325 also showed a favorable safety and
tolerability profile with no cases of eye inflammation at week
24 
    ** UBX plans to start a pivotal study for UBX1325 in H2 2023
    ** As of last close, UBX down ~80% YTD 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))